Liberum appointed as Nomad and Joint Corporate Broker to Open Orphan plc

Open Orphan is a niche contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials. Open Orphan is dual listed on the London AIM stock Exchange and the Dublin Euronext Growth Exchange and has offices in London, Dublin, Paris, and the Netherlands.

Open Orphan comprises of two commercial specialist CRO services businesses; hVIVO and Venn Life Sciences. Based in London, hVIVO is a world leader in infectious and respiratory diseases through the provision of its own proprietary in-house developed and grown versions of disease specific viruses, known as challenge studies. Venn Life Sciences provides drug development services and consultancy offering CMC, preclinical, PK & PD, medical writing and regulatory consultancy from its Breda office in the Netherlands.

Open Orphan was founded in 2017 and was admitted to AIM in June 2019 by way of a reverse takeover of Venn Life Sciences. The Group acquired hVIVO plc in January 2020.

Liberum Team

Investment Banking – Phil Walker, Edd Mansfield, Ben Cryer, Will King

Research – Ed Thomason

Sales – Alistair Smallwood

CIR – Lynsey Cox